AroCell AB (publ) announced today that a distribution agreement has been signed with the French company Eurobio Scientific, for distribution of AroCell TK 210 ELISA in France and Switzerland.

AroCell TK 210 ELISA measures thymidine kinase 1 (TK1) levels in serum and provides valuable information about cell proliferation and disruption. As cancer tumors have increased cell proliferation and successful treatment disrupt cancer cells, the use of AroCell TK 210 ELISA for patient monitoring during treatment may support clinicians to optimize treatment and estimate the risk of recurrence of cancer disease.

 “We are delighted to have the opportunity to partner with Eurobio Scientific for the distribution of AroCell TK 210 ELISA”, says Michael Brobjer, AroCell’s CEO. “Eurobio Scientific is a French fully integrated leader in the field of in vitro diagnostics with expertise ranging from discovery to commercialization of specialty diagnostic solutions as well as products for life science research. This agreement is in line with AroCell´s commercialization strategy to make AroCell TK 210 ELISA widely available and to facilitate the use of the product in clinical research, routine clinical laboratories as well as for drug development within the pharmaceutical industry.

AroCell TK 210 ELISA is CE-marked and will be commercially available immediately through Eurobio Scientific in France, Switzerland, Algeria, Morocco and Tunisia.

For more information:
Michael Brobjer, CEO
Telephone: +46(0)70 669 96 87
E-mail: michael.brobjer@arocell.com

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Michael Brobjer, December 20, 2018 at 08:00.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.
For more information; www.arocell.com

Attachment

• EN 2018-12-19 ES

A peer-reviewed article has been published in the journal Nucleosides, Nucleotides and Nucleic Acids, entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine Kinase 1 protein levels using AroCell TK 210 ELISA: a tool for drug development”, written by Kiran Jagarlamudi et al. The results have previously been presented at a scientific meeting in Gdansk last year.

TK 1 has the potential as a proliferation and cell disruption biomarker for the monitoring of cancer disease during therapy. In this publication the goal was to measure induction and release of TK 1 from leukemia and breast tumor cell lines in vitro, modeling the clinical effects of doxorubicin, a commonly used chemotherapy drug.

“We are delighted with the results of this scientific study, which demonstrate that the AroCell TK 210 ELISA can be used to measure TK 1 protein as a biomarker for in vitro drug effects, particularly, for drugs targeting cell proliferation and DNA damage.” says Michael Brobjer, AroCell’s new CEO. “These results support AroCell’s focus on the application of the TK 210 ELISA in drug discovery and development. They demonstrate the potential of TK1 as a translational biomarker that can be used to evaluate potential drug candidates before they are moved into xenograft and other preclinical investigations.”

AroCell TK 210 ELISA is an easy-to-use, robust and reproducible assay. In addition, it can be run on standard ELISA equipment commonly used in many laboratories.

The publication is available on: https://www.tandfonline.com/doi/full/10.1080/15257770.2018.1478094

For more information:
Michael Brobjer, CEO
AroCell AB (publ)
Tel: +46(0)70 669 96 87
E-mail: michael.brobjer@arocell.com

This information was submitted for publication through the agency of Michael Brobjer, December 11, 2018 at 08:30 hours.

About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow-up of cancer patients. AroCell´s new technology is based on patented methods to measure Thymidine Kinase 1 (TK 1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.
For more information: www.arocell.com

Attachment

• 20181211 PM Nuclosides en

AroCell’s Chief Scientific Officer, Professor Staffan Eriksson, presents today new preliminary results from the U-CAN TK1 lymphoma study at the International Society of Oncology Biomarkers (ISOBM) in Hamburg. The preliminary results suggest that TK 210 ELISA may be used for monitoring the effect of therapy of DLBCL patients under rituximab + CHOP treatment, and for determination of overall survival rate.

In the study TK 210 ELISA has been used for monitoring the effect of drug therapy (rituximab + CHOP) on patients suffering from DLBCL (Diffuse Large B-Cell Lymphoma), an aggressive form of non-Hodgkin’s lymphoma with an incidence of approximately 7 per 100 000 globally (United States National Cancer Institute’s SEER Database).

At the same congress, AroCell is presenting results from an additional study which show the analytical performance of TK 210 ELISA compared to activity-based methods, e.i. LIAISON® Thymidine Kinase, and 3H-dThd phosphorylation. The study is based on measuring TK1 concentration in serum samples from healthy blood donors and subjects with hematological malignancies, such as lymphoma, leukemia and multiple myeloma.

The results show that TK 210 ELISA has similar performance compared to LIAISON Thymidine Kinase and the 3H-dThd phosphorylation assay. The study also shows that AroCell’s unique Sample Dilution Buffer contributes to improve the diagnostic performance.

“The results from these studies suggest that TK 210 ELISA could be a valuable tool in the management of hematological malignancies such as DLBCL, as well as in breast cancer as previously described in Tumor Biology, 2016. While TK 210 ELISA correlates with other activity-based methods for measuring cell proliferation and disruption, it is also easy-to-use, reproducible, robust, and can be adapted to automated high-throughput ELISA platforms commonly used in clinical laboratories”, says Professor Eriksson.

Professor Eriksson’s presentation is available on https://arocell.com/sv/isobm20181127

For more information:
Johan von Heijne, Acting CEO
Telephone: +46(0)705-95 15 10
E-mail: johan.vonheijne@arocell.com

AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, November 27, 2018 at 15:00.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.

For more information; www.arocell.com

Attachment

• 2018-11-27 ISOBM en

Michael Brobjer has been appointed new CEO of AroCell and will join the company December 8, 2018. Mr.Brobjer will provide AroCell with valuable expertise through his extensive experience in the pharmaceutical and biotechnology industry.

Michael Brobjer has long experience from leading positions in pharmaceutical and biotech companies, such as Pharmacia & Upjohn and Biovitrum. He has also held the position as Marketing Manager and Responsible for Business Life Science within APL, which offers companies contract services in Life Science, and now last CEO of Karessa and Karessa Holding. Michael has a strong profile focusing on leadership and communication. His experience in strategic development and corporate construction is well suited to the role of AroCell's CEO.

"We are very pleased that Michael Brobjer is joining us as CEO. His solid experience of Life Science and enthusiastic leadership style will help to establish AroCell's CE-labeled products on the market, as well as to develop the company's clinical programs and commercialization strategy. With Michael as CEO together with the recent recruitment of Anders Hultman as CFO, the company will have an exciting and driven leadership duo " said Claes Post, Chairman AroCell.

"I´m looking forward to start at AroCell. My assessment is that there is a great potential in the company and it feels really exciting to take part and lead the company's continued development. AroCell has a technology that has the potential to contribute to increased benefit for both patients and healthcare providers through monitoring tumor development, "said Michael Brobjer.

For more information:

Johan von Heijne, Acting CEO

Telephone: +46(0)705-95 15 10

E-mail: johan.vonheijne@arocell.com

AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, October 23, 2018 at 15:45.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.

For more information; www.arocell.com

Attachment

• 2018-10-17 New CEO Arocell

AroCell announced today that the U.S. Patent and Trademark Office has granted AroCell´s patent US 10,100,128 titled ”Monoclonal Anti-TK1 Antibodies”.

The patent refers to AroCell’s proprietary monoclonal antibodies that enable the specific and sensitive measurement of Thymidine Kinase 1 in blood.

” We are delighted that the U.S. Patent and Trademark Office has granted the US patent. This reinforces our patent position in the U.S. and increases AroCell's attractiveness as business partner. We will now continue to develop our portfolio of proprietary assets to further expand its business opportunities abroad” says Johan von Heijne.

For more information:

Johan von Heijne, Acting CEO

Telephone: +46(0)705-95 15 10

E-mail: johan.vonheijne@arocell.com

AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, at 08.30 on October 17, 2018.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.

Attachment

• 2018-10-17 Patent granted in US

AroCell AB announces today that a second abstract has been accepted by ISOBM (International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany November 24-27, 2018.

The study, entitled “Molecular forms of serum thymidine kinase 1 in hematological malignancies determined with the AroCell TK 210TM ELISA,” confirms the importance and significance of using AroCell’s proprietary sample dilution buffer included in TK 210 ELISA for pre-treatment of samples. The sample preparation step is clearly improving the diagnostic value when quantifying the concentration of thymidine kinase in serum samples from subjects with hematological malignancies.

“These results show that AroCell’s TK 210 ELISA technique reduces the unspecific detection of TK1 in samples from healthy blood donors, thus improving the diagnostic value of the test. We are confirming the improved discrimination between hematological malignancies and healthy blood donors using the AroCell’s sample preparation method,” says Professor Eriksson, head of R&D at AroCell.

In addition to the poster presentation above, the company will, in an oral presentation session at ISOBM, present results from a performance evaluation of TK 210 ELISA and activity-based methods, as earlier communicated.

These two presentations comfirm that TK 210 ELISA is a valuable tool in the management of hematological malignancies, as well as of breast cancer as, previously described (Tumor Biology, 2016). The test is sensitive, specific and robust. The ELISA format is well suited for implementation on automated ELISA platforms which are already installed at many routine clinical laboratories.

For more information:
Johan von Heijne, Acting CEO
Telephone: +46-705-95 15 10
E-post: johan.vonheijne@arocell.com

AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, at 08.40 on October 9,2018.

About AroCell
AroCell AB (AROC) is a Swedish company that is developing standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. The AroCell share (AROC) is listed on Nasdaq First North with Redeye AB as Certified Adviser.
For more information, please see www.arocell.com.

Attachment

• 2018-10-09 A second abstract accepted at ISOBM

An abstract entitled “A performance evaluation of three currently used thymidine kinase 1 assays in sera from patients with hematological malignancies shows high concordance”, by Staffan Eriksson et al., has been accepted for oral presentation at the ISOBM (International Society of Oncology and BioMarkers) congress in Hamburg, Germany November 24-27, 2018.

The study presents results from a performance evaluation of TK 210 ELISA and activity-based methods, e.i. LIAISON® Thymidine Kinase, and 3H-dThd phosphorylation, by using serum samples from subjects with hematological malignancies and healthy blood donors. The results shows that TK 210 ELISA has similar performance compared to the LIAISON Thymidine Kinase and the 3H-dThd phosphorylation assays when measuring TK1 in serum.

The authors conclude that TK 210 ELISA is a valuable tool in the management of hematological malignancies, as well as in breast cancer as previously described (Tumor Biology, 2016). While TK 210 ELISA delivers the same result as activity-based methods, it is robust, easy-to-use and can be adapted to automated high throughput ELISA platforms.

For more information:
Johan von Heijne, Acting CEO
Telephone: +46-705-95 15 10
E-post: johan.vonheijne@arocell.com

AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, at 11.30 on September 18,2018.

About AroCell
AroCell AB (AROC) is a Swedish company that is developing standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. The AroCell share (AROC) is listed on Nasdaq First North with Redeye AB as Certified Adviser.

For more information, please see www.arocell.com.

Attachment

• 2018-09-17 TK 210 ELISA compared to other methods

AroCell AB has received a Notice of Allowance stating that the U.S. Patent and Trademark Office intends to grant the company's patent application no. 15/105,999 titled ”Monoclonal Anti-TK1 Antibodies”.

The patent application relates to AroCell’s proprietary monoclonal antibodies that enable the specific and sensitive assay of Thymidine Kinase 1.

” We are delighted that the U.S. Patent and Trademark Office has informed us of their intention to grant our patent application”, says Johan von Heijne, Acting CEO, AroCell. “This reinforces our patent position in the U.S. and increases AroCell's attractiveness as a licensing partner. We continue to work with our patent portfolio to protect our assets and broaden our business opportunities” states Mr. von Heijne.

For more information:

Johan von Heijne, Acting CEO

Telephone: +46(0)705-95 15 10

E-mail: johan.vonheijne@arocell.com

AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, at 15.15 on August 29,2018.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.

Attachment

• 2018-08-29 Patent reinforces AroCell’s opportunities in the US market

A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications describing research on TK1 as a biomarker, with particular focus on the application of TK1 immunoassays to the study of solid tumors.

In the publication, the authors, Kiran Jagarlamudi, PhD and Research Manager at AroCell, and Martin Shaw, AroCell’s Business Development Manager, analyse and summarize recent literature on TK1 as a tumor biomarker and present ideas and possibilities for its application in drug discovery and clinical studies.

Professor Eriksson, Scientific Director of AroCell, comments: “Thymidine kinase 1 (TK1) has long been known as a valuable biomarker for determination of cell proliferation related to malignant diseases. However, no comprehensive reviews on the application of TK1 as biomarker have been published in recent years and the earlier studies are mostly concentrated on TK1 in hematologic cancers”.

Moreover, the older enzyme activity-based methods had drawbacks which made them less suitable for assaying the TK1 forms found in subjects with solid tumors. The new generation of immunoassays, have resolved many of these challenges and have opened up new possibilities for TK1 as a valuable biomarker in solid tumor diseases.

TK1 is showing great potential as a predictive biomarker for how to optimize new and established therapies for many forms of cancer.

This is a timely and relevant review which is demonstrated by that the article was downloaded more than 300 times in the first weeks that it was available on line.

The review article may be found on PubMed at https://www.ncbi.nlm.nih.gov/pubmed/30039979
and will be published in print in the September 2018 edition of Biomarkers in Medicine (www.futuremedicine.com/journal/bmm).

For more information:
Johan von Heijne, Acting CEO
Telephone: +46-705-95 15 10
E-post: johan.vonheijne@arocell.com

About AroCell

AroCell AB (AROC) is a Swedish company that is developing standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. The AroCell share (AROC) is listed on Nasdaq First North. For more information, please see www.arocell.com.

Attachment

• 2018-08-24 Review article

AroCell på den asiatiska marknaden

Som uppföljning till pressmeddelandet 22 november om att AroCell och Green Cross Cell tecknat en avsiktsförklaring har partnerna ingått distributionsavtal för Sydkorea, Taiwan och Kina. Förutom dessa marknader kan avtal komma att tecknas även för Japan.

Befolkningen i Sydkorea uppgår till drygt 50 miljoner, Taiwan har runt 25 miljoner invånare och den kinesiska befolkningen uppgår till 1,4 miljarder invånare. -"Avtalet med Green Cross Cell ger oss möjlighet att börja bearbeta en mycket stor och expansiv marknad" säger Jan Stålemark, vd på AroCell.

AroCell arbetar med tre strategiska komponenter:

• Klinisk validering
• Kommersialisering
• Partnering & Licensiering

Samarbetet med Green Cross Cell ligger i linje med de två första av våra tre strategiska komponenter.

Den första strategiska komponenten är klinisk validering. Green Cross Cell kommer att använda och kliniskt validera TK 210(TM) tillsammans med den cancerbehandling de har utvecklat. Cancerbehandlingen är baserad på reaktiverade T-celler. Green Cross Cell kommer att använda TK 210(TM) för att utvärdera patienter inför, under och efter behandling. Idag används Green Cross Cells behandling för bland annat lever-, mag-tarm- och glioblastomcancer.

Den andra strategiska komponenten är vår kommersialisering. Green Cross Cell kommer att marknadsföra TK 210(TM) för andra användningsområden inom cancersjukvård och läkemedels-utveckling i de länder avtalet omfattar. -"Med AroCells moderna TK 210(TM) ELISA kan vi framgångsrikt bearbeta marknaderna i Sydkorea, Kina, Taiwan och förhoppningsvis inom kort även Japan" säger Dr Lee, CEO på Green Cross Cell.

Green Cross Cells terapi är modern, effektiv och väl lämpad att använda tillsammans med vår TK 210(TM) ELISA. Green Cross Cell söker godkännande för sin cancerterapi i flera länder vilket är positivt och ger nya möjligheter för AroCell, "säger Jan Stålemark, CEO på AroCell.